SOURCE: Biophan Technologies, Inc.

October 19, 2007 07:30 ET

Biophan Announces Myotech CSS Data Presented at the Cleveland Clinic

Animal Study Results Presented at the 21st Century Treatment of Heart Failure Conference

PITTSFORD, NY--(Marketwire - October 19, 2007) - Biophan Technologies, Inc. (OTCBB: BIPH), a developer of next-generation biomedical technology, today announced a presentation of animal study data on the Myotech Circulatory Support System (CSS) at the Cleveland Clinic's 21st Century Treatment of Heart Failure Conference. The data presented indicates that the Myotech CSS holds promise to vastly improve outcomes for patients with Congestive Heart Failure (CHF).

Congestive Heart Failure affects an estimated 4.8 million Americans, and half of all patients diagnosed with CHF will die within five years. There are over 200,000 deaths per year related to CHF. Due to the poor prognosis for patients with CHF, the search for better treatments is critically important.

The Myotech CSS consists of a flexible polymer cup that slips over the heart and connects to an external drive unit to pump the heart and restore normal blood flow. It can be installed in approximately three minutes through a small incision to provide immediate, life-saving support in emergency situations. Since it has no contact with circulating blood, the Myotech CSS also promises to reduce the risk of patient complications, such as clotting and stroke, bleeding, and infection.

In the recently presented small-animal study, Myotech Chief Medical Officer Dr. Mark Anstadt and his colleagues at Wright State University demonstrated that the Myotech CSS effectively supported cardiac function when CHF had been artificially induced. They also found evidence that the Myotech CSS may one day revolutionize CHF treatment. One bio-marker that tracks cell damage which might have been caused by the device was unchanged, indicating the safety of the device to the heart muscle. Another marker that tracks the gradual weakening of heart muscle as CHF progresses was drastically reduced by use of the Myotech CSS, showing that this system could actually reverse the course of CHF.

"This study indicates the tremendous potential for the Myotech CSS to treat multiple forms of heart disease," stated John Lanzafame, Biophan CEO. "Our initial focus is on acute circulatory support, which will be the initial application of the technology, but this study shows that the Myotech CSS may also be effective in treating CHF, and improving the quality of life for thousands of patients. We are very excited about the long term potential of this technology platform."

About Biophan Technologies, Inc.

Biophan is dedicated to providing technologies that offer innovative and competitive advantages to the medical device industry. The Company is helping to commercialize the Myotech Circulatory Support System, which has significant potential to improve the treatment of acute heart failure. Biophan Technologies, Inc. holds a 68% interest in Myotech with rights to acquire additional equity, and is leading Myotech's business development efforts. Biophan is traded on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock Exchange under the symbol BTN. For more information on Biophan, please visit our website at www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology; the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC, which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Contact Information

  • Contact:

    Carolyn Hotchkiss
    Communications Manager
    Biophan Technologies, Inc.
    (585) 267-4813
    Email Contact